Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1f13bc1744-trace').style.display = (document.getElementById('cakeErr67f1f13bc1744-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f1f13bc1744-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1f13bc1744-code').style.display = (document.getElementById('cakeErr67f1f13bc1744-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1f13bc1744-context').style.display = (document.getElementById('cakeErr67f1f13bc1744-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f1f13bc1744-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f1f13bc1744-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27234,
		&#039;title&#039; =&gt; &#039;Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Industry worried&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Different views?&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In fact, the official added, India was taking a cue from China in keeping the US at bay.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Public health concerns&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 8 February, 2015, http://www.thehindubusinessline.com/companies/indian-drug-cos-worried-about-patent-regime-changes/article6871490.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675284,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27234,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Access to Medicines,Patented Medicines,TRIPS,patents&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line


Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Industry worried&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Different views?&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In fact, the official added, India was taking a cue from China in keeping the US at bay.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Public health concerns&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27234,
	&#039;title&#039; =&gt; &#039;Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Industry worried&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Different views?&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In fact, the official added, India was taking a cue from China in keeping the US at bay.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Public health concerns&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 8 February, 2015, http://www.thehindubusinessline.com/companies/indian-drug-cos-worried-about-patent-regime-changes/article6871490.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675284,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27234
$metaTitle = &#039;LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;
$metaKeywords = &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Access to Medicines,Patented Medicines,TRIPS,patents&#039;
$metaDesc = &#039;
-The Hindu Business Line


Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Industry worried&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Different views?&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In fact, the official added, India was taking a cue from China in keeping the US at bay.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Public health concerns&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line


Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Indian drug cos worried about patent regime changes -PT Jyothi Datta</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line</div><p align="justify"><em>Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America</em></p><p align="justify"><em>Mumbai: </em>Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on Finance less than a fortnight ago.</p><p align="justify">On January 27, Froman, in a written statement, said engagement between the two countries had helped &quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&quot;</p><p align="justify"><em>Industry worried</em></p><p align="justify">Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&quot;</p><p align="justify">The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.</p><p align="justify">After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&quot; Pritzker was part of President Obama's delegation on his India visit.</p><p align="justify">On the face of it, the Centre's position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.</p><p align="justify">The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India's Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.</p><p align="justify">Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&quot;</p><p align="justify">Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.</p><p align="justify"><em>Different views?</em></p><p align="justify">However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.</p><p align="justify">The Prime Minister's statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India's stand on data exclusivity or patent linkages.</p><p align="justify">In fact, the official added, India was taking a cue from China in keeping the US at bay.</p><p align="justify">Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.</p><p align="justify"><em>Public health concerns</em></p><p align="justify">But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.</p><p align="justify">&quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.</p><p align="justify">Last year, the US' Special 301 report (on IP) stopped short of further downgrading India, though it called for &quot;out of cycle&quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.</p><p align="justify"><em>With inputs from Amiti Sen and Richa Mishra in New Delhi </em></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1f13bc1744-trace').style.display = (document.getElementById('cakeErr67f1f13bc1744-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f1f13bc1744-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1f13bc1744-code').style.display = (document.getElementById('cakeErr67f1f13bc1744-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1f13bc1744-context').style.display = (document.getElementById('cakeErr67f1f13bc1744-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f1f13bc1744-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f1f13bc1744-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27234,
		&#039;title&#039; =&gt; &#039;Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Industry worried&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Different views?&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In fact, the official added, India was taking a cue from China in keeping the US at bay.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Public health concerns&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 8 February, 2015, http://www.thehindubusinessline.com/companies/indian-drug-cos-worried-about-patent-regime-changes/article6871490.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675284,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27234,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Access to Medicines,Patented Medicines,TRIPS,patents&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line


Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Industry worried&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Different views?&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In fact, the official added, India was taking a cue from China in keeping the US at bay.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Public health concerns&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27234,
	&#039;title&#039; =&gt; &#039;Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Industry worried&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Different views?&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In fact, the official added, India was taking a cue from China in keeping the US at bay.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Public health concerns&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 8 February, 2015, http://www.thehindubusinessline.com/companies/indian-drug-cos-worried-about-patent-regime-changes/article6871490.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675284,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27234
$metaTitle = &#039;LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;
$metaKeywords = &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Access to Medicines,Patented Medicines,TRIPS,patents&#039;
$metaDesc = &#039;
-The Hindu Business Line


Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Industry worried&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Different views?&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In fact, the official added, India was taking a cue from China in keeping the US at bay.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Public health concerns&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line


Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Indian drug cos worried about patent regime changes -PT Jyothi Datta</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line</div><p align="justify"><em>Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America</em></p><p align="justify"><em>Mumbai: </em>Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on Finance less than a fortnight ago.</p><p align="justify">On January 27, Froman, in a written statement, said engagement between the two countries had helped &quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&quot;</p><p align="justify"><em>Industry worried</em></p><p align="justify">Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&quot;</p><p align="justify">The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.</p><p align="justify">After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&quot; Pritzker was part of President Obama's delegation on his India visit.</p><p align="justify">On the face of it, the Centre's position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.</p><p align="justify">The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India's Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.</p><p align="justify">Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&quot;</p><p align="justify">Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.</p><p align="justify"><em>Different views?</em></p><p align="justify">However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.</p><p align="justify">The Prime Minister's statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India's stand on data exclusivity or patent linkages.</p><p align="justify">In fact, the official added, India was taking a cue from China in keeping the US at bay.</p><p align="justify">Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.</p><p align="justify"><em>Public health concerns</em></p><p align="justify">But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.</p><p align="justify">&quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.</p><p align="justify">Last year, the US' Special 301 report (on IP) stopped short of further downgrading India, though it called for &quot;out of cycle&quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.</p><p align="justify"><em>With inputs from Amiti Sen and Richa Mishra in New Delhi </em></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1f13bc1744-trace').style.display = (document.getElementById('cakeErr67f1f13bc1744-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f1f13bc1744-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1f13bc1744-code').style.display = (document.getElementById('cakeErr67f1f13bc1744-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f1f13bc1744-context').style.display = (document.getElementById('cakeErr67f1f13bc1744-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f1f13bc1744-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f1f13bc1744-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27234,
		&#039;title&#039; =&gt; &#039;Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Industry worried&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Different views?&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In fact, the official added, India was taking a cue from China in keeping the US at bay.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Public health concerns&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 8 February, 2015, http://www.thehindubusinessline.com/companies/indian-drug-cos-worried-about-patent-regime-changes/article6871490.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675284,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27234,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Access to Medicines,Patented Medicines,TRIPS,patents&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line


Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Industry worried&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Different views?&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In fact, the official added, India was taking a cue from China in keeping the US at bay.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Public health concerns&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27234,
	&#039;title&#039; =&gt; &#039;Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Industry worried&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Different views?&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In fact, the official added, India was taking a cue from China in keeping the US at bay.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Public health concerns&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 8 February, 2015, http://www.thehindubusinessline.com/companies/indian-drug-cos-worried-about-patent-regime-changes/article6871490.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675284,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27234
$metaTitle = &#039;LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta&#039;
$metaKeywords = &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Access to Medicines,Patented Medicines,TRIPS,patents&#039;
$metaDesc = &#039;
-The Hindu Business Line


Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Seek clarification on US trade representative&#039;s testimony that India has committed to address IP issues that concern America&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman&#039;s testimony to the Senate Committee on Finance less than a fortnight ago.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On January 27, Froman, in a written statement, said engagement between the two countries had helped &amp;quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Industry worried&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &amp;quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &amp;quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&amp;quot; Pritzker was part of President Obama&#039;s delegation on his India visit.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On the face of it, the Centre&#039;s position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India&#039;s Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &amp;quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Different views?&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Prime Minister&#039;s statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India&#039;s stand on data exclusivity or patent linkages.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In fact, the official added, India was taking a cue from China in keeping the US at bay.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Public health concerns&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&amp;quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the US&#039; Special 301 report (on IP) stopped short of further downgrading India, though it called for &amp;quot;out of cycle&amp;quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;With inputs from Amiti Sen and Richa Mishra in New Delhi &lt;/em&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line


Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Indian drug cos worried about patent regime changes -PT Jyothi Datta</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line</div><p align="justify"><em>Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America</em></p><p align="justify"><em>Mumbai: </em>Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on Finance less than a fortnight ago.</p><p align="justify">On January 27, Froman, in a written statement, said engagement between the two countries had helped &quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&quot;</p><p align="justify"><em>Industry worried</em></p><p align="justify">Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&quot;</p><p align="justify">The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.</p><p align="justify">After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&quot; Pritzker was part of President Obama's delegation on his India visit.</p><p align="justify">On the face of it, the Centre's position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.</p><p align="justify">The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India's Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.</p><p align="justify">Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&quot;</p><p align="justify">Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.</p><p align="justify"><em>Different views?</em></p><p align="justify">However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.</p><p align="justify">The Prime Minister's statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India's stand on data exclusivity or patent linkages.</p><p align="justify">In fact, the official added, India was taking a cue from China in keeping the US at bay.</p><p align="justify">Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.</p><p align="justify"><em>Public health concerns</em></p><p align="justify">But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.</p><p align="justify">&quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.</p><p align="justify">Last year, the US' Special 301 report (on IP) stopped short of further downgrading India, though it called for &quot;out of cycle&quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.</p><p align="justify"><em>With inputs from Amiti Sen and Richa Mishra in New Delhi </em></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 27234,
		'title' => 'Indian drug cos worried about patent regime changes -PT Jyothi Datta',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu Business Line
</div>
<p align="justify">
<em>Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America</em>
</p>
<p align="justify">
<em>Mumbai: </em>Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on Finance less than a fortnight ago.
</p>
<p align="justify">
On January 27, Froman, in a written statement, said engagement between the two countries had helped &quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&quot;
</p>
<p align="justify">
<em>Industry worried</em>
</p>
<p align="justify">
Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&quot;
</p>
<p align="justify">
The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.
</p>
<p align="justify">
After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&quot; Pritzker was part of President Obama's delegation on his India visit.
</p>
<p align="justify">
On the face of it, the Centre's position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.
</p>
<p align="justify">
The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India's Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.
</p>
<p align="justify">
Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&quot;
</p>
<p align="justify">
Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.
</p>
<p align="justify">
<em>Different views?</em>
</p>
<p align="justify">
However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.
</p>
<p align="justify">
The Prime Minister's statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India's stand on data exclusivity or patent linkages.
</p>
<p align="justify">
In fact, the official added, India was taking a cue from China in keeping the US at bay.
</p>
<p align="justify">
Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.
</p>
<p align="justify">
<em>Public health concerns</em>
</p>
<p align="justify">
But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.
</p>
<p align="justify">
&quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.
</p>
<p align="justify">
Last year, the US' Special 301 report (on IP) stopped short of further downgrading India, though it called for &quot;out of cycle&quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.
</p>
<p align="justify">
<em>With inputs from Amiti Sen and Richa Mishra in New Delhi </em>
</p>',
		'credit_writer' => 'The Hindu Business Line, 8 February, 2015, http://www.thehindubusinessline.com/companies/indian-drug-cos-worried-about-patent-regime-changes/article6871490.ece',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4675284,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 27234,
	'metaTitle' => 'LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta',
	'metaKeywords' => 'generic medicine,generic medicines,Access to Health,Access to Healthcare,Access to Medicines,Patented Medicines,TRIPS,patents',
	'metaDesc' => '
-The Hindu Business Line


Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?...',
	'disp' => '<div align="justify">-The Hindu Business Line</div><p align="justify"><em>Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America</em></p><p align="justify"><em>Mumbai: </em>Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on Finance less than a fortnight ago.</p><p align="justify">On January 27, Froman, in a written statement, said engagement between the two countries had helped &quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&quot;</p><p align="justify"><em>Industry worried</em></p><p align="justify">Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&quot;</p><p align="justify">The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.</p><p align="justify">After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&quot; Pritzker was part of President Obama's delegation on his India visit.</p><p align="justify">On the face of it, the Centre's position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.</p><p align="justify">The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India's Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.</p><p align="justify">Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&quot;</p><p align="justify">Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.</p><p align="justify"><em>Different views?</em></p><p align="justify">However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.</p><p align="justify">The Prime Minister's statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India's stand on data exclusivity or patent linkages.</p><p align="justify">In fact, the official added, India was taking a cue from China in keeping the US at bay.</p><p align="justify">Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.</p><p align="justify"><em>Public health concerns</em></p><p align="justify">But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.</p><p align="justify">&quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.</p><p align="justify">Last year, the US' Special 301 report (on IP) stopped short of further downgrading India, though it called for &quot;out of cycle&quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.</p><p align="justify"><em>With inputs from Amiti Sen and Richa Mishra in New Delhi </em></p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 27234,
	'title' => 'Indian drug cos worried about patent regime changes -PT Jyothi Datta',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu Business Line
</div>
<p align="justify">
<em>Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America</em>
</p>
<p align="justify">
<em>Mumbai: </em>Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on Finance less than a fortnight ago.
</p>
<p align="justify">
On January 27, Froman, in a written statement, said engagement between the two countries had helped &quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&quot;
</p>
<p align="justify">
<em>Industry worried</em>
</p>
<p align="justify">
Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&quot;
</p>
<p align="justify">
The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.
</p>
<p align="justify">
After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&quot; Pritzker was part of President Obama's delegation on his India visit.
</p>
<p align="justify">
On the face of it, the Centre's position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.
</p>
<p align="justify">
The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India's Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.
</p>
<p align="justify">
Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&quot;
</p>
<p align="justify">
Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.
</p>
<p align="justify">
<em>Different views?</em>
</p>
<p align="justify">
However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.
</p>
<p align="justify">
The Prime Minister's statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India's stand on data exclusivity or patent linkages.
</p>
<p align="justify">
In fact, the official added, India was taking a cue from China in keeping the US at bay.
</p>
<p align="justify">
Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.
</p>
<p align="justify">
<em>Public health concerns</em>
</p>
<p align="justify">
But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.
</p>
<p align="justify">
&quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.
</p>
<p align="justify">
Last year, the US' Special 301 report (on IP) stopped short of further downgrading India, though it called for &quot;out of cycle&quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.
</p>
<p align="justify">
<em>With inputs from Amiti Sen and Richa Mishra in New Delhi </em>
</p>',
	'credit_writer' => 'The Hindu Business Line, 8 February, 2015, http://www.thehindubusinessline.com/companies/indian-drug-cos-worried-about-patent-regime-changes/article6871490.ece',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'indian-drug-cos-worried-about-patent-regime-changes-pt-jyothi-datta-4675284',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4675284,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 27234
$metaTitle = 'LATEST NEWS UPDATES | Indian drug cos worried about patent regime changes -PT Jyothi Datta'
$metaKeywords = 'generic medicine,generic medicines,Access to Health,Access to Healthcare,Access to Medicines,Patented Medicines,TRIPS,patents'
$metaDesc = '
-The Hindu Business Line


Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America


Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns?...'
$disp = '<div align="justify">-The Hindu Business Line</div><p align="justify"><em>Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America</em></p><p align="justify"><em>Mumbai: </em>Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on Finance less than a fortnight ago.</p><p align="justify">On January 27, Froman, in a written statement, said engagement between the two countries had helped &quot;secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders.&quot;</p><p align="justify"><em>Industry worried</em></p><p align="justify">Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: &quot;We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are.&quot;</p><p align="justify">The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights.</p><p align="justify">After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: &quot;We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it.&quot; Pritzker was part of President Obama's delegation on his India visit.</p><p align="justify">On the face of it, the Centre's position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights.</p><p align="justify">The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India's Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy.</p><p align="justify">Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. &quot;From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval.&quot;</p><p align="justify">Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing.</p><p align="justify"><em>Different views?</em></p><p align="justify">However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue.</p><p align="justify">The Prime Minister's statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India's stand on data exclusivity or patent linkages.</p><p align="justify">In fact, the official added, India was taking a cue from China in keeping the US at bay.</p><p align="justify">Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed.</p><p align="justify"><em>Public health concerns</em></p><p align="justify">But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement.</p><p align="justify">&quot;All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry,&quot; a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime.</p><p align="justify">Last year, the US' Special 301 report (on IP) stopped short of further downgrading India, though it called for &quot;out of cycle&quot; reviews. The year also saw trade-related investigations by the US International Trade Commission.</p><p align="justify"><em>With inputs from Amiti Sen and Richa Mishra in New Delhi </em></p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Indian drug cos worried about patent regime changes -PT Jyothi Datta

-The Hindu Business Line Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on Finance less than a fortnight ago. On January 27, Froman, in a written statement, said engagement between the two countries had helped "secure commitments from India in the 2014 Trade Policy Forum on a broad range of IP issues of concern to the US and its stakeholders." Industry worried Commenting on the development, DG Shah of the Indian Pharmaceutical Alliance, which represents large domestic Indian drug companies, said: "We are at a loss to understand, and are unaware on what has been committed. But when Ambassador Froman makes a statement to the Senate committee under oath, the Indian government needs to clarify what these commitments are." The controversy has erupted as India is in the midst of finalising a new policy on intellectual property rights. After her meeting with US Commerce Secretary Penny Pritzker, Commerce and Industry Minister Nirmala Sitharaman had told the media: "We have invited the Americans to look at the draft policy (on IPR) and give their inputs. We will then see what we can do with it." Pritzker was part of President Obama's delegation on his India visit. On the face of it, the Centre's position that Indian laws are already fully TRIPS compliant would rule out any major concessions to the US pharmaceutical lobby, which has been pressuring the American government to push for TRIPS-plus measures. TRIPS is short for Trade-Related Aspects of Intellectual Property Rights. The US lobby is unlikely to make much headway with one of its main concerns - Section 3 (d) of the Indian Patent Act, which prohibits evergreening - given that India's Supreme Court has upheld the constitutional validity of the provision, which prevents patenting of new forms of known substances unless they exhibit enhanced efficacy. Anand Grover, former UN Special Rapporteur on the Right to Health and Director of Lawyers Collective, is concerned that India may be considering making concessions relating to data exclusivity and patent linkages. "From sources, it appears that the Centre is considering bringing these in through administrative measures. It must make its stand public and not do anything without parliamentary approval." Data exclusivity and patent linkage (see info-box) delay the entry of inexpensive generic medicines in the market, leaving the market open to high monopolistic pricing. Different views? However, a top government official involved with bilateral talks during the Obama visit and a witness at the CEO forum the dignitaries addressed says that India has conveyed to the US that they were on different tracks on the IP issue. The Prime Minister's statement on accepting IP suggestions meant that India was ready to correct or rectify loopholes or loose ends in the implementation of the law. But India is not changing the law, the official said, adding emphatically that there was no softening of India's stand on data exclusivity or patent linkages. In fact, the official added, India was taking a cue from China in keeping the US at bay. Deepak Parekh, another participant in the CEO forum, had told BusinessLine at the time that only piracy and counterfeiting had been discussed. Public health concerns But pro-health groups have been cautioning that India is under pressure on the flexibilities it had been allowed and exercised under the TRIPS agreement. "All these flexibilities (such as opposition procedures, compulsory licences) are now under attack by the US government at the behest of their industry," a Lawyers Collective note alleged, apprehending that India may adopt a TRIPS-plus IP regime. Last year, the US' Special 301 report (on IP) stopped short of further downgrading India, though it called for "out of cycle" reviews. The year also saw trade-related investigations by the US International Trade Commission. With inputs from Amiti Sen and Richa Mishra in New Delhi